ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Ready For Remote: eCOA Adapts To A Hybrid World

  Due to the global health impact of COVID-19, many aspects of daily life have been moved to a hybrid model, meaning a mix of in-person and technology-enabled interactions In this blog, learn why eCOAs are especially well-suited for hybrid clinical trials.

• Investigator Databank And DQS: Welcoming New Consortium Members

  Join the Data Query System consortium to access a comprehensive, collaborative platform that enhances clinical trial feasibility, site selection, and investigator engagement.

• How eCOAs Can Benefit Clinical Trials

  Learn how the built-in flexibility and freedom of eCOAs can enhance many aspects of a clinical trial.

• Top 5 Ways To Leverage eLogs In Clinical Research

  Unearth how embracing these specific approaches ensures that technology becomes a true ally in enhancing precision, accessibility, and collaboration within the intricate realm of clinical research.

• Pioneering Clinical Research For Native American Communities In South Dakota

  Lynn Bartholow is transforming clinical research for Native American populations. Explore her journey into clinical research and efforts to build trust and foster participation and community engagement.

• Televisits: Why Integrate Telemedecine Features In eCOA Trials?

  Discover new possibilities where patients can complete several of their clinical study procedures remotely, making their participation in clinical trials easier and less cumbersome than site-based trials.

• Combining Patient-Centric Technology and RWD For Comprehensive Evidence

  Explore how by combining digital technologies with secondary RWD, researchers can gather a more holistic understanding of the patient. 

• Strategies For More Accurate Clinical Trial Forecasting And Budgeting

  Explore some of the best strategies and practices to ensure clinical trial staff get approval for their budgets, with forecasts as accurate as possible.

• Build Vs. Buy Vs. Partner In Life Sciences: Making The Right Call

  Discover when life sciences organizations should develop technology in-house, buy off-the-shelf solutions, or form strategic partnerships, exploring the costs and risks that come with each approach.

• Real-World Evidence - Where Are We Now?

  Notwithstanding ongoing confusion over the concepts of “real-world data” and “real-world evidence” in 2022, more than 5 years after the passage of the 21st Century Cures Act, the FDA continues to evaluate such data and evidence as it considers regulatory decisions.